Month/Year | Company Milestone |
---|---|
July 2018 | Myriad acquires Counsyl and enters the reproductive genetic testing market. |
May 2018 | GeneSight® data from a landmark randomized control trial is presented at the American Psychiatric Association annual meeting. |
April 2018 | Myriad launches new corporate Go Green sustainably initiative. |
January 2018 | Myriad receives FDA approval for BRACAnalysis CDx® as a companion diagnostic for Lynparza™ in patients with metastatic breast cancer. |
September 2017 | Myriad launches riskScore® test. |
May 2017 | Medicare Coverage of Prolaris® expands to include men with favorable-intermediate prostate cancer. |
March 2017 | EndoPredict® test is launched in the United States. |
August 2016 | Myriad acquires Assurex Health and the GeneSight® genetic test. |
May 2016 | Myriad acquires Sividon Diagnostics, a leading breast cancer prognostic company. |
October 2015 | Myriad and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer. |
October 2015 | Myriad receives Medicare coverage of Prolaris® for prostate cancer patients. |
September 2015 | Myriad unveils its new logo, the first update since the Company’s founding in 1991. |
January 2015 | Myriad receives European CE Marking approval for its Tumor BRACAnalysis CDx test for use as a companion diagnostic to predict responders to PARP inhibitors such as Lynparza (olaparib). |
December 2014 | Myriad receives FDA approval for its BRACAnalysis CDx® test to identify ovarian cancer patients who may benefit from the PARP inhibitor Lynparza (olaparib). |
November 2014 | Myriad and TESARO announce an expanded companion diagnostic agreement during the second quarter to use Myriad’s myChoice® HRD test in clinical studies in support of niraparib, TESARO’s novel PARP inhibitor |
November 2014 | Myriad and AbbVie sign expanded agreement for Tumor BRACAnalysis CDx and veliparib. |
October 2014 | Myriad establishes Tumor BRACAnalyis CDx laboratory in Europe to help identify patients with BRCA mutations who many benefit from treatment with PARP inhibitors such as AstraZeneca’s olaparib. |
October 2014 | Myriad receives draft Medicare coverage for Prolaris®, a revolutionary test for prostate cancer. |
April 2014 | Myriad submits a premarket approval application to the FDA for BRACAnalysis CDx® as a companion diagnostic with a PARP inhibitor. (BRACAnalysis CDx is one of the first laboratory developed tests submitted for FDA premarket approval). |
February 2014 | Myriad acquires of California-based Crescendo Biosciences, Inc. and diversifies into the autoimmune market. |
January 2014 | Myriad licenses EndoPredict®, a second generation prognostic test kit for patients diagnosed with breast cancer. |
November 2013 | Myriad launches the Myriad myPath® Melanoma diagnostic test to differentiate benign skin lesions from malignant melanoma. |
October 2013 | Myriad launches the Myriad myPlan® Lung Cancer prognostic test for patients with lung cancer. |
September 2013 | Myriad launches Myriad myRisk® Hereditary Cancer, a 25-gene panel test for eight major cancers. |
February 2013 | The one-millionth patient is tested with BRACAnalysis® test. |
February 2012 | Myriad announces opening of European laboratory in Munich, Germany. |
February 2012 | Clinical study shows Prolaris® to predict prostate cancer aggressiveness and patient risk of recurrence. |
June 2011 | Myriad acquires Texas-based Rules Based Medicine and forms Myriad RBM®, a wholly owned subsidiary. |
2011 | Myriad enters into three companion diagnostic collaborations for PARP inhibitors. |
December 2010 | Myriad launches PANEXIA®, a predictive test for hereditary pancreatic cancer. |
November 2010 | Crescendo Bioscience, Inc. announces the launch of Vectra® DA, the first multi-biomarker blood test that measures rheumatoid arthritis disease activity. |
March 2010 | Myriad launched Prolaris®, the first prognostic test to predict prostate cancer survival. |
July 2009 | Myriad announces the spinoff to shareholders of its pharmaceutical business. |
December 2008 | Myriad launches PREZEON®, a genetic test to assess the status of the PTEN gene. |
January 2008 | Myriad launches BRACAnalysis® for the women’s health preventative care market, significantly expanding access to genetic cancer testing. |
August 2007 | Myriad announces third Phase 2 clinical trial for Azixa, a molecular disruption agent. |
August 2006 | Myriad launches BART, a large rearrangement test for high-risk breast cancer patients. |
May 2005 | Myriad announces results of a Phase 2 Alzheimer’s drug clinical trial. |
December 2004 | Myriad tests 100,000 women for breast cancer predisposition. |
June 2004 | Myriad submits investigational new drug applications on two cancer drugs to FDA. |
February 2003 | Myriad announces the discovery of major depression gene in collaboration with Abbott Laboratories. |
May 2002 | Myriad launches COLARIS AP®, a genetic test for FAP colon cancer syndrome. |
November 2001 | Myriad launches MELARIS®, a test for melanoma. Myriad publishes in Cell, the discovery of a novel HIV cellular process. |
February 2001 | Myriad announces complete map of the rice genome. |
September 2000 | Myriad launches COLARIS®, a genetic test for hereditary colorectal and uterine cancer. |
April 1999 | Myriad incorporates Myriad Pharmaceuticals to develop novel therapies. |
January 1998 | Myriad launches ProNet, a proprietary protein-interaction technology. |
March 1997 | Myriad announces the discovery of the PTEN gene that is associated with a large number of cancers. |
November 1996 | Myriad launches BRACAnalysis®, the first full length gene sequencing test for a major, common disease, for the oncology market. |
December 1995 | Myriad announces the discovery of the BRCA 2 gene that is associated with hereditary breast and ovarian cancer. |
October 1995 | Myriad becomes a public company and is traded on NASDAQ under the ticker: MYGN. |
September 1994 | Myriad scientists publishes in Science the discovery of the BRCA 1 gene that is associated with hereditary breast and ovarian cancer. |
Fall 1993 | Myriad announces the discovery of the P16 gene that is associated with hereditary melanoma. |
May 1991 | Myriad Genetics, Inc. is founded, making it one of the first genomics companies in history. |